For years, companies have offered remote data entry systems to transfer data from trial sites to a central server. But Big Pharma has by and large stuck to its old-fashioned paper ways. Now several start-ups are offering a new breed of web-based RDE and the pharmaceutical industry is starting to take interest. But before embracing an online approach to data collection, drug companies want proof that doing so will save them time and money. Pharma companies must also evaluate how to integrate data collection and management into the rest of their infrastructures. Collaboration rather than competition might best enable pharmaceutical; companies to fully realize the benefits of web-enabled trials through the cooperative sharing of resources.
by Jeffrey Dvorin
For an industry so dependent on technological innovation on the front end of R&D, Big Pharma has been remarkably slow...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
During Q2, biopharma merger and acquisition deal value reached $24.6bn and drew in $60.7bn in potential deal value from alliances. Device company M&A values reached $223m, while in vitro diagnostics and research tools players’ M&A activity totaled $802m.
Pharma leaders are shifting from AI pilots to enterprise-scale deployment, favoring external partnerships for efficiency gains while maintaining tight control over sensitive clinical data.
The biotech funding landscape is undergoing a fundamental shift. With traditional VC becoming increasingly cautious and selective, industry executives are exploring new avenues for capital. Conversely, this evolution may ultimately benefit the sector's long-term sustainability.
In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.
